Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study.
Picard F, Van Ganse E, Ducrocq G, Danchin N, Falissard B, Hanon O, Belhassen M, Ginoux M, Lefevre C, Cotte FE, Mahé I, Steg PG. Picard F, et al. Among authors: mahe i. Clin Cardiol. 2019 Oct;42(10):851-859. doi: 10.1002/clc.23231. Epub 2019 Jul 17. Clin Cardiol. 2019. PMID: 31313832 Free PMC article.
Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG. Falissard B, et al. Among authors: mahe i. Arch Cardiovasc Dis. 2019 Jun-Jul;112(6-7):400-409. doi: 10.1016/j.acvd.2019.02.003. Epub 2019 Apr 20. Arch Cardiovasc Dis. 2019. PMID: 31014991 Free article.
Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.
Kraaijpoel N, Bleker SM, Meyer G, Mahé I, Muñoz A, Bertoletti L, Bartels-Rutten A, Beyer-Westendorf J, Porreca E, Boulon C, van Es N, Iosub DI, Couturaud F, Biosca M, Lerede T, Lacroix P, Maraveyas A, Aggarwal A, Girard P, Büller HR, Di Nisio M; UPE investigators. Kraaijpoel N, et al. Among authors: mahe i. J Clin Oncol. 2019 Jul 10;37(20):1713-1720. doi: 10.1200/JCO.18.01977. Epub 2019 May 22. J Clin Oncol. 2019. PMID: 31116676
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Agnelli G, et al. N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. N Engl J Med. 2020. PMID: 32223112 Clinical Trial.
Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation.
Hanon O, Vidal JS, Pisica-Donose G, Orvoën G, David JP, Chaussade E, Caillard L, de Jong LW, Boulloche N, Vinsonneau U, Bouée S, Krolak-Salmon P, Fauchier L, Jouanny P, Sacco G, Bellarbre F, Belmin J, Puisieux F, Lilamand M, Paillaud E, Boureau AS; SAFIR study group. Hanon O, et al. Heart. 2021 Sep;107(17):1376-1382. doi: 10.1136/heartjnl-2020-317923. Epub 2020 Dec 1. Heart. 2021. PMID: 33262185
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.
Mahé I, Agnelli G, Ay C, Bamias A, Becattini C, Carrier M, Chapelle C, Cohen AT, Girard P, Huisman MV, Klok FA, López-Núñez JJ, Maraveyas A, Mayeur D, Mir O, Monreal M, Righini M, Samama CM, Syrigos K, Szmit S, Torbicki A, Verhamme P, Vicaut E, Wang TF, Meyer G, Laporte S. Mahé I, et al. Thromb Haemost. 2022 Apr;122(4):646-656. doi: 10.1055/a-1647-9896. Epub 2021 Nov 5. Thromb Haemost. 2022. PMID: 34535037 Free PMC article. Clinical Trial.
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France.
Belhassen M, Hanon O, Steg PG, Mahé I, Née M, Jacoud F, Dalon F, Cotté FE, Guitard-Dehoux D, Marant-Micallef C, Van Ganse E, Danchin N. Belhassen M, et al. Among authors: mahe i. Eur J Health Econ. 2023 Aug;24(6):867-875. doi: 10.1007/s10198-022-01513-2. Epub 2022 Aug 28. Eur J Health Econ. 2023. PMID: 36030485 Free PMC article.
Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study.
Danchin N, Steg G, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Cotte FE, Gollety S, Van Ganse E, Belhassen M. Danchin N, et al. Among authors: mahe i. Arch Cardiovasc Dis. 2022 Nov;115(11):571-577. doi: 10.1016/j.acvd.2022.06.006. Epub 2022 Sep 29. Arch Cardiovasc Dis. 2022. PMID: 36257903 Free article.
294 results